| Bioactivity | BRD-8899 is a STK33 inhibitor, with an IC50 of 11 nM[1]. |
| Target | IC50: 11 nM (STK33). |
| Invitro | BRD8899 (1, 10, 20 μM, 24 h) results in decreased phosphorylation of the MST4 substrate ezrin in NOMO-1 cells[1]. Western Blot Analysis[1] Cell Line: |
| Name | BRD-8899 |
| CAS | 1404437-50-8 |
| Formula | C17H22N4O3S |
| Molar Mass | 362.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tuoping Luo, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2860-5. |